Overexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition

Cardiovasc Res. 2008 Sep 1;79(4):600-10. doi: 10.1093/cvr/cvn128. Epub 2008 May 28.

Abstract

Aims: Proteasome inhibitors are a novel class of anticancer agents that induce tumour cell death via endoplasmic reticulum (ER) stress. Since ER stress is involved in the development of heart failure, we investigated the role of ER-initiated cardiomyocyte death by proteasome inhibition.

Methods and results: Rat neonatal cardiomyocytes were used in this study. Proteasome activity was assayed using proteasome peptidase substrates. Cell viability and apoptosis were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenol tetrazolium bromide and flow cytometry, respectively. Western blot analysis, real-time polymerase chain reaction (PCR) and reverse transcriptional PCR were used to detect the expression of protein and messenger ribonucleic acid (RNA). The location of overexpressed glucose-regulated protein (GRP) 78 was observed by confocal fluorescence microscopy. Proteasome inhibition induced cardiomyocyte death and activated ER stress-induced transcriptional factor ATF6, but not XBP1 (X-box binding protein 1), without up-regulating ER chaperones. ER-initiated apoptosis signalling, including cytosine-cytosine-adenine-adenine-thymine enhancer-binding protein (C/EBP) homologous protein (CHOP), c-Jun-N-terminal kinase (JNK), and caspase-12, was activated by proteasome inhibition. Short interference RNA targeting CHOP, but not the blockage of caspase-12 or JNK pathway, attenuated cardiomyocyte death. Overexpression of GRP78 suppressed both CHOP expression and cardiomyocyte death by proteasome inhibition.

Conclusion: These findings demonstrate that proteasome inhibition induces ER-initiated cardiomyocyte death via CHOP-dependent pathways without compensatory up-regulation of ER chaperones. Supplement and/or pharmacological induction of GRP78 can attenuate cardiac damage by proteasome inhibition.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activating Transcription Factor 6 / metabolism
  • Animals
  • Animals, Newborn
  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects*
  • Caspase 12 / metabolism
  • Cell Survival / drug effects
  • Cells, Cultured
  • Cysteine Proteinase Inhibitors / pharmacology*
  • Dose-Response Relationship, Drug
  • Endoplasmic Reticulum / drug effects*
  • Endoplasmic Reticulum / enzymology
  • Endoplasmic Reticulum / pathology
  • Heat-Shock Proteins / metabolism
  • JNK Mitogen-Activated Protein Kinases / metabolism
  • Leupeptins / pharmacology
  • Molecular Chaperones / genetics
  • Molecular Chaperones / metabolism*
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / enzymology
  • Myocytes, Cardiac / pathology
  • Oligopeptides / pharmacology
  • Oxidative Stress / drug effects
  • Proteasome Endopeptidase Complex / metabolism
  • Proteasome Inhibitors*
  • RNA Interference
  • RNA, Small Interfering / metabolism
  • Rats
  • Signal Transduction / drug effects
  • Transcription Factor CHOP / metabolism
  • Tunicamycin / pharmacology

Substances

  • Activating Transcription Factor 6
  • Antineoplastic Agents
  • Atf6 protein, rat
  • Cysteine Proteinase Inhibitors
  • GRP78 protein, rat
  • Heat-Shock Proteins
  • Leupeptins
  • Molecular Chaperones
  • Oligopeptides
  • Proteasome Inhibitors
  • RNA, Small Interfering
  • Tunicamycin
  • Transcription Factor CHOP
  • JNK Mitogen-Activated Protein Kinases
  • Caspase 12
  • Proteasome Endopeptidase Complex
  • benzyloxycarbonylleucyl-leucyl-leucine aldehyde
  • epoxomicin